Details for New Drug Application (NDA): 209920
✉ Email this page to a colleague
The generic ingredient in LUBIPROSTONE is lubiprostone. There are ten drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the lubiprostone profile page.
Summary for 209920
| Tradename: | LUBIPROSTONE |
| Applicant: | Teva Pharms Usa Inc |
| Ingredient: | lubiprostone |
| Patents: | 0 |
Pharmacology for NDA: 209920
| Mechanism of Action | Chloride Channel Activators |
Medical Subject Heading (MeSH) Categories for 209920
Suppliers and Packaging for NDA: 209920
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 209920 | ANDA | Teva Pharmaceuticals, Inc. | 0480-3479 | 0480-3479-06 | 60 CAPSULE, GELATIN COATED in 1 BOTTLE (0480-3479-06) |
| LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 209920 | ANDA | Teva Pharmaceuticals, Inc. | 0480-4138 | 0480-4138-06 | 60 CAPSULE, GELATIN COATED in 1 BOTTLE (0480-4138-06) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 8MCG | ||||
| Approval Date: | Jan 18, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 24MCG | ||||
| Approval Date: | Jan 18, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
